Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.

Original languageEnglish (US)
Article numberofac389
JournalOpen Forum Infectious Diseases
Volume9
Issue number8
DOIs
StatePublished - Aug 1 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords

  • COVID-19
  • Palovid
  • contraindications
  • nirmatrelvir/ritonavir

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19'. Together they form a unique fingerprint.

Cite this